Schizophrenia
Conditions
Interventions
brexpiprazole 2mg 24weeks
Sponsors
Fujita health university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 patients who obtained informed consent 2 20 age or over and under 65 age 3 inpatients and outpatients 4 male and female 5 PANSS-EC >= 4 (one or more items) and CGI-S >= 4 6 patients who had not taken antipsychotic agents for more than two days, or who had taken antipsychotic agents less than 200mg (chlorpromazine equivalence) over three days
Exclusion criteria
Exclusion criteria: 1 coma 2 strongly effected of central nervous depressant (e.g. barbiturate) 3 during use epinephrine 4 effected of nervous stimulating (e.g. alcohol) 5 hypersensitivity of brexpiprazole 6 diabetes 7 pregnant women 8 lactating woman 9 history of clozapine 10 treatment-Resistant Schizophrenia 11 inappropriate by physian 12 Mental Retardation 13 dementia 14 Personality disorder 15 brain disorder and severe physical disorder 16 combined paroxetine 17 combined carbamazepine 18 treated electro-convulsive therapy within six month 19 treated long-acting injection within six month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SWNS-J (baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| DAI-10 (baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks) subjective questionaire | — |
Countries
Japan
Contacts
Public ContactMasakazu Hatano
Fujita health university hospital Pharmacy
Outcome results
None listed